More Aggressive Chemo Regimen Improves Outcomes of Pancreatic Cancer Patients After Surgery
source: pixabay.com

More Aggressive Chemo Regimen Improves Outcomes of Pancreatic Cancer Patients After Surgery

According to a story from toweroncology.com, a recent study has revealed that a more aggressive chemotherapy could be significantly more effective for patients with pancreatic cancer after surgery in comparison…

Continue Reading More Aggressive Chemo Regimen Improves Outcomes of Pancreatic Cancer Patients After Surgery
A Supplemental New Drug Application Has Been Submitted For a Combination Therapy For Waldenström Macroglobulinemia
jarmoluk / Pixabay

A Supplemental New Drug Application Has Been Submitted For a Combination Therapy For Waldenström Macroglobulinemia

The US Food and Drug Administration (FDA) is reviewing a supplemental New Drug Application (sNDA) for the drug Imbruvica (ibrutinib) in combination with rituximab (Rituxan) for treating Waldenström macroglobulinemia. The…

Continue Reading A Supplemental New Drug Application Has Been Submitted For a Combination Therapy For Waldenström Macroglobulinemia
Investigational Treatment for Adenoid Cystic Carcinoma Gets Orphan Drug Designation Under New Developer
Source: Pixabay.com

Investigational Treatment for Adenoid Cystic Carcinoma Gets Orphan Drug Designation Under New Developer

According to a story from inpublic.globenewswire.com, the U.S. Food and Drug Administration has recently transferred its Orphan Drug designation for dovitinib from to Oncology Venture (OV) from Novartis, according to…

Continue Reading Investigational Treatment for Adenoid Cystic Carcinoma Gets Orphan Drug Designation Under New Developer
This Company Announced That it Won’t Provide Its Experimental Treatment for Amyotrophic Lateral Sclerosis Under Right to Try
Source: Pixabay

This Company Announced That it Won’t Provide Its Experimental Treatment for Amyotrophic Lateral Sclerosis Under Right to Try

According to a story from reuters.com, the U.S.-Israeli company BrainStorm Therapeutics will not provide its investigational stem cell treatment under the recently passed U.S. Right to Try law. The company…

Continue Reading This Company Announced That it Won’t Provide Its Experimental Treatment for Amyotrophic Lateral Sclerosis Under Right to Try